Cetuximab is not indicated in EGFR expression colorectal cancer with a Ras‐mutant due to treatment‐related toxicity; EGFR amplification co‐occurred with an NRAS (p.G12S) mutation in a single tumor. This evidence concerns the gene EGFR and neoplasm.